AD: Shocked! The peak value of plasma Aβ42/Aβ40 began to decline 41 years before the deposition of brain Aβ! Alzheimer's diseases: New discovery on plasma Aβ42/Aβ40. AD: Shocked! The peak value of plasma Aβ42/Aβ40 began to decline 41 years before the deposition of brain Aβ! Amyloid β (Aβ) plaque deposition and phosphorylated tau (p-tau) protein tangles are two important pathological features of Alzheimer's disease (AD), and there are many kinds of AD biomarkers derived around them, Knowledge of the longitudinal trajectories of key markers could not only help improve the selection and monitoring of participants in clinical trials, but also help identify those at high risk for neurodegenerative changes and cognitive impairment. Although research on AD biomarkers has increased substantially in recent years, research on longitudinal changes in biomarkers is relatively limited. Studies have shown that the levels of plasma Aβ 42 /Aβ 40 , p-tau181 and glial fibrillary acidic...
European Medicines Agency investigates whether Johnson & Johnson COVID-19 vaccine is associated with thrombosis
European Medicines Agency investigates whether Johnson & Johnson COVID-19 vaccine is associated with thrombosis
European Medicines Agency investigates whether Johnson & Johnson COVID-19 vaccine is associated with thrombosis.
The European Medicines Agency said on the 9th that it is investigating whether the new crown vaccine developed by Johnson & Johnson Pharmaceuticals Co., Ltd. is associated with thrombosis. In the United States, four Johnson & Johnson vaccinators developed blood clots.
This regulatory agency continues to investigate whether there is a causal link between the new crown vaccine developed by AstraZeneca Pharmaceuticals in the United Kingdom and the presence of blood clots in the vaccinators, and it has also found that some vaccinators have other diseases.
Thrombosis associated with Johnson & Johnson vaccine?
The European Medicines Agency said in a report on the 9th that four Johnson & Johnson vaccine vaccinators in the United States had severe thrombosis with low platelets. Three of them developed thrombosis after mass vaccination with this vaccine, and one was due to coagulation disorders during the clinical trial death. The FDA is evaluating the link between this vaccine and blood clots.
Reuters reported that the European Medicines Agency's report was the first public investigation of the association between Johnson & Johnson vaccine and thrombosis.
The single dose of Johnson & Johnson vaccine has been approved for emergency use in the European Union, but the large-scale vaccination has not yet started. This vaccine is currently being promoted mainly in the United States. According to data from the US Centers for Disease Control and Prevention, as of the morning of the 8th, nearly 5 million people in the United States have been vaccinated against Johnson & Johnson.
On March 10th, in Chicago, USA, people are preparing to enter the COVID-19 vaccination spot on the United Center Stadium. (Posted by Xinhua News Agency, photo by Joel Rainer)
The European Medicines Agency report uses data from the US Food and Drug Administration. The US Drug Administration is aware of the above-mentioned cases of thrombosis and believes that the thrombosis may be related to many factors. It said in a statement on the 9th: "We have not found a causal link between (thrombosis) and vaccination (Johnson & Johnson vaccine), and will continue to investigate and evaluate those cases. Data analysis will guide possible (implemented) regulatory actions."
Johnson & Johnson said the company is cooperating with regulatory agencies to provide data and related information. "At present, it is impossible to confirm that these rare cases have a clear causal connection with the Johnson & Johnson new crown vaccine."
Is AstraZeneca vaccine related to other diseases?
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee said on the 9th that it has begun investigating whether the capillary leak syndrome of vaccinators is associated with the AstraZeneca vaccine.
Capillary leak syndrome can cause swelling of blood vessels and a drop in blood pressure. The European Medicines Agency has so far received reports of the above symptoms from 5 AstraZeneca vaccinators. The committee said that it is currently unclear whether these symptoms are related to the AstraZeneca vaccine.
On March 24, a woman was vaccinated with AstraZeneca at the hospital in Coria, Cáceres, Spain. (Posted by Xinhua News Agency, photo by Gustavo Ballente)
AstraZeneca Pharmaceuticals has not yet responded to questions from Reuters reporters on whether capillary leak syndrome is related to vaccines.
The Pharmacovigilance Risk Assessment Committee said that thrombosis with low platelets should be listed as a very rare side effect of the AstraZeneca vaccine, and related investigations will continue.
The European Medicines Agency said on the 7th that researchers found a "possible link" between the AstraZeneca vaccine and the appearance of thrombosis, but still emphasized that the advantages of using this vaccine outweigh the disadvantages. Many European and Asian countries have subsequently imposed age restrictions on AstraZeneca vaccination. The French government said on the 9th that considering the possible side effects of the AstraZeneca vaccine, it will provide a second dose of other vaccines to people under 55 who have already received the first dose of AstraZeneca vaccine.
Ian Douglas, professor of drug epidemiology at the University of London School of Hygiene and Tropical Medicine, said that these reports are part of regulatory agencies’ routine procedures for evaluating important safety signs of drugs. Is it related to AstraZeneca vaccination and whether thrombosis is related to Johnson & Johnson vaccination?